Japan GCP Audit-Readiness Rubric — Ministerial Ordinance on Good Clinical Practice for Drugs (MHLW Ordinance No. 28, 1997, as amended)
What this is: the Japanese analogue to Regscribe's existing ICH E6(R3)/E6(R2) rubric (docs/ich-e6-rubric.md). Relevant wherever a customer runs, or plans to run, a drug/biologic clinical trial in Japan under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the "PMD Act", formerly the Pharmaceutical Affairs Act), and needs gap analysis against Japanese GCP ("J-GCP") specifically — not just generic ICH GCP.
Relationship to the ICH E6 rubric — read this first: Japan is a founding ICH region, and J-GCP was originally harmonized with ICH E6(R1) in March 1997 (this ordinance). This is not a duplicate rubric. The two documents are complementary in the same way Regscribe's ISO 14155 and ICH E6 rubrics are complementary: ICH E6 is the international-consensus GCP philosophy; this document is Japan's own binding domestic law that implements that philosophy with Japan-specific structural mechanics layered on top — a mandatory Institutional Review Board (IRB) accreditation/founder regime with no direct ICH E6(R2) equivalent, a formalized role for "clinical research coordinators" (CRCs) and commercial Site Management Organizations (SMOs) that structurally dominate Japanese trial-site operations, a distinct "sponsor-investigator" (investigator-initiated trial) regulatory track running in parallel to the sponsor-initiated track throughout the ordinance, and document-retention triggers keyed to Japan's own marketing-approval process. This rubric documents those Japan-specific mechanics and where they diverge from or add to ICH E6 as already rubric'd; it does not re-derive the underlying GCP principles (informed consent, IRB review, monitoring, essential documents) already covered at the ICH-E6 level of generality.
Sources used
Regulatory text (primary source, directly fetched and read in full this session):
- PMDA's own official English translation, titled "Ministerial Ordinance on Good Clinical Practice for Drugs" — Ordinance of the Ministry of Health and Welfare No. 28 of March 27, 1997, "As last amended by the Ordinance of Ministry of Health, Labour and Welfare No. 84 of May 20, 2022", marked "Provisional Translation (as of January 2023)". Fetched directly from
pmda.go.jp/files/000152996.pdfand read as a rendered PDF (58 pages) — the full Table of Contents, and the complete text of Articles 1–59 plus the Supplementary Provisions (amendment history table back to the 1997 original), were read directly in this session, not summarized from a secondary source. This is the strongest sourcing this rubric has for any single element: a direct, complete read of the actual current-structure ordinance text, matching the standard set by the ICH E6 rubric's direct ICH PDF reads. - The PDF's own footnote states, verbatim: "This English version of the Japanese Ministerial Ordinance is provided for reference purposes only. In the event of any inconsistency between the Japanese original and the English translation, the former shall prevail." — carried forward here as the same caveat applies to Regscribe's use of it.
- PMDA's GCP/GPSP compliance-assessment landing page (
pmda.go.jp/english/review-services/glp-gcp-gpsp/0003.html) was also fetched directly this session. It states the ordinance's Japanese-language original was last amended December 2023, and explicitly notes "the English translation available is noted as an older version, with the latest guidance available only in Japanese." This is an important, honestly-flagged gap: the English-language primary source this rubric is built on (reflecting amendments through May 2022) may not reflect at least one subsequent Japanese-only amendment (December 2023). See Gaps section.
Secondary/tertiary sources used only for context clearly labeled as such:
- WebSearch result summaries (not independently fetched/read in full) for: general background confirming J-GCP's 1997 ICH-harmonization history; the SMO/CRC industry structure in Japan (Advarra, CMIC Group, ClinicalTrialsArena, EPS Global, Wikipedia's "Site management organization" article); Japan's 2018 Clinical Trials Act (CTA) scope, drawing on a Japanese Journal of Clinical Oncology article abstract (Kondo et al., "Regulatory changes after the enforcement of the new Clinical Trials Act in Japan,"
academic.oup.com/jjco/article/50/4/399/5760691) and a PMC review article, neither independently fetched in full this session — flagged as a follow-up if exact CTA statutory citations are needed. - The Diovan/valsartan data-manipulation scandal — background drawn from WebSearch summaries of The Lancet, Fierce Pharma, Journal of Human Hypertension ("The Diovan scandal in Japan; don't let bygones be bygones," Nagata & Fujita, 2022), and a 2023 International Journal of Health Planning and Management article (Ozaki, "Japan's valsartan clinical trials shambles"). None of these were independently fetched and read in full this session — the broad facts (Novartis Pharma K.K. employee Nobuo Shirahashi arrested June 2014 for data falsification in Diovan-related academic trials; a Tokyo court in 2017 acquitted Novartis and Shirahashi on the specific criminal false-advertising charge, while acknowledging the underlying data had been manipulated) are treated as high-confidence given multiple independent outlets agreeing, but exact court-case citations, article/statute numbers, and the precise legal reasoning were not verified against a primary court document or MHLW enforcement notice this session. See failure-pattern marker usage below and the Gaps section.
- PMDA GCP-violation frequency data: sourced from a peer-reviewed, PMC-indexed article — Kondo et al. (or similarly titled), "A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan" (PMC6682372 / ScienceDirect, Therapeutic Innovation & Regulatory Science-family journal) — summarized via WebSearch snippet, not independently fetched and read in full this session. This is a stronger class of source than an aggregator blog (it is peer-reviewed and directly on-point: GCP violations found in Japanese NDA/sNDA review 2007–2017), but the specific percentages below should be treated as secondary-sourced pending a direct full-text read, consistent with how the ICH E6 rubric flags its own PMC-citation (Sellers et al.) as unread-in-full.
- No PMDA-published aggregate GCP-inspection-finding dataset analogous to FDA's BIMO metrics or EMA's GCP IWG annual report was located this session. PMDA's own English GCP-inspection page (fetched directly) does not publish finding-category statistics — it only links to inspection checklists and procedural notices. This is a genuine, honestly-flagged sourcing gap, not an oversight: unlike FDA/EMA, PMDA does not appear to publish a public annual inspection-findings report in English (or a Japanese one that surfaced this session).
Rubric legend
Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern
Failure-pattern cells are marked:
- [HISTORICAL] — a real, confirmed, publicly-documented case, from the founding era or an older, closed episode, illustrating why a clause matters rather than a current enforcement trend.
- [REPRESENTATIVE] — a well-established, textbook-level J-GCP failure mode grounded in the ordinance's own structure/peer-reviewed inspection data, not tied to one named recent enforcement action verified this session.
- [ANALOGOUS] — a real, confirmed case that is structurally on-point but did not arise under this specific ordinance/clause (e.g., arose under academic-ethics guidelines rather than the GCP Ordinance, or the finding was a civil/criminal-advertising matter rather than a GCP article violation) — included for illustrative value with the caveat stated explicitly.
- [UNVERIFIED — flagged, not used] — reserved marker for claims that could not be confirmed and were dropped rather than guessed; used explicitly wherever a plausible-sounding fact could not be verified this session.
Part A — Structure and version status of the ordinance
Confirmed directly from the primary-source PDF's own Table of Contents and Supplementary Provisions (Article history):
The ordinance ("Ministerial Ordinance on Good Clinical Practice for Drugs," MHLW Ordinance No. 28 of March 27, 1997) is structured as:
| Chapter | Content | Articles |
|---|---|---|
| I | General Provisions (Objectives, Definitions) | 1–3 |
| II §1 | Standards for Preparing Clinical Trials — sponsor-initiated | 4–15 |
| II §2 | Standards for Preparing Clinical Trials — sponsor-investigator (investigator-initiated) | 15-2–15-9 |
| III §1 | Standards for Clinical Trial Management — sponsor-initiated | 16–26 |
| III §2 | Standards for Clinical Trial Management — sponsor-investigator | 26-2–26-12 |
| IV §1 | Institutional Review Board (IRB) | 27–34 |
| IV §2 | Medical Institution | 35–41 |
| IV §3 | Investigator | 42–49 |
| IV §4 | Informed Consent of Subjects | 50–55 |
| V | Standards for Documents Submitted in Reexamination etc. (post-marketing surveillance cross-application) | 56 |
| VI | Standards for Sponsoring Clinical Trials etc. (parallel provisions for trials sponsored under PMD Act Article 80-2) | 57–59 |
| — | Supplementary Provisions | Effective-date and transition rules, amendment history |
Confirmed amendment history (directly from the Supplementary Provisions table, read in full): the ordinance has been amended at least seventeen times since 1997, including MHW/MHLW Ordinance Nos. 127 (2000), 36 (2001), 14 (2002), 106 (2003), 172 (2004), 72 (2006), 24 (2008), 163 (2012), 68 (2009), 161 (2012), 87 (2014), 9 (2016), 116 (2017), 155 (2020), 208 (2020), 15 (2021), and — the amendment reflected in this rubric's primary source — No. 84 of May 20, 2022. PMDA's own website states the Japanese original was further amended in December 2023, and that the current official English translation is an older version predating that amendment — meaning at least one round of substantive change (nature/scope unconfirmed from an English source this session) postdates the text this rubric is built on. Flagged prominently, not glossed over — see Gaps, item 1.
Structural point distinctive versus the ICH E6 rubric's Part A (version-staging discussion): J-GCP does not have an "R2 vs R3" duality — it is a single, continuously-amended ordinance, not a document with numbered "revision" editions coexisting. Regscribe's version-currency risk for this rubric is therefore not "which edition applies" but "is the translation this rubric is built on current" — a materially different and, per PMDA's own admission, currently-unresolved risk.
Part B — Sponsor and sponsor-investigator duties: confirmed structural parallelism
The single most distinctive structural feature of this ordinance, confirmed by direct read, is that nearly every sponsor obligation is duplicated almost verbatim into a parallel "sponsor-investigator" (investigator-initiated trial) track — Chapter II §2 (Articles 15-2 through 15-9) and Chapter III §2 (Articles 26-2 through 26-12) mirror Chapter II §1 (Articles 4–15) and Chapter III §1 (Articles 16–26) respectively, article-for-article, with only the responsible party's label changed. ICH E6(R3) does not draw this same formal sponsor/sponsor-investigator dual-track distinction as an organizing structural principle throughout its own text (it addresses investigator-sponsors more narrowly). This is a genuine Japan-specific drafting choice worth flagging to Regscribe's engineering side: a customer's trial should first be classified as sponsor-initiated (企業治験) vs. investigator-initiated (医師主導治験) before applying sponsor-obligation rows, because the citation numbers differ even though the substance is nearly identical.
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 1 | A person intending to sponsor a clinical trial (or to be a sponsor-investigator) must prepare written operating procedures covering protocol preparation, institution/investigator selection, investigational-product control/accountability, adverse-drug-reaction information collection, and record keeping, and must secure personnel with adequate expertise (physicians, dentists, pharmacists). | Article 4 (sponsor) / Article 15-2 (sponsor-investigator) | Written SOPs covering each named function; staffing records showing named physicians/dentists/pharmacists assigned to trial-management duties | Generic corporate SOPs never tailored to the specific trial's investigational product/design — auditors expect SOPs specific enough to name the actual control/accountability and AE-collection mechanics used |
| 2 | The protocol must name, where applicable, all contractors ("outsourced" parties) to whom any sponsor duty is delegated, and the sponsor must conclude a written contract with each contractor specifying scope, operating procedures, the sponsor's right to ascertain compliance, instructions given, and reporting obligations. | Article 7, Paragraph 1, Item (2) (protocol disclosure); Article 12 (Outsourcing Duties contract requirements, sponsor track); Article 15-8 (parallel provision, sponsor-investigator track) | Protocol section naming each contractor and outsourced scope; the Article 12/15-8 outsourcing contract itself, containing all seven-plus enumerated elements | A CRO/SMO engaged without the Article 12 contract's specific enumerated elements (esp. the sponsor's stated right to ascertain compliance and receive contractor reports) — a bare service agreement that doesn't track the ordinance's own required contract content is a document-level gap an automated check can catch directly against the article text |
| 3 | The sponsor must retain trial records (protocol, contracts, reports, CRFs, monitoring/audit records, generated data) until the later of: the date of marketing approval of the test drug, or 3 years after the date of premature termination/completion (or the date of a decision not to submit the data). | Article 26, Paragraph 1 (sponsor); Article 26-12 (sponsor-investigator, keyed instead to the date the investigational product provider receives marketing approval) | Records-retention schedule explicitly keyed to the later of the two named trigger events, revisited if/when marketing approval status changes | A retention schedule calculated once at trial completion and never revisited if marketing approval is later granted (or delayed) years afterward — structurally the same risk Regscribe's GLP rubric flags for 21 CFR 58.195's approval/submission-keyed retention triggers; recommend reusing that rubric's retention-scoring logic rather than building a new node |
| 4 | The sponsor must appoint a Clinical Trial In-Country Representative if the sponsor resides outside Japan, to conduct sponsoring procedures and take measures to prevent/address health hazards from the investigational drug. | Article 15 | Named in-country representative's identity/address on file; evidence the representative actually retains Article 16 Paragraph 5 manufacturing/supply/disposal records for the full retention period, not just a nominal appointment letter | A foreign sponsor naming an in-country representative on paper (e.g., a Japan branch office head) with no functional record-retention or hazard-response capability — the representative role is a distinctively Japan-specific compliance gate for any non-Japan-headquartered Regscribe customer running J-GCP trials, with no direct ICH E6(R3) equivalent (ICH E6 does not mandate an in-country agent concept) |
| 5 | Prior supply of investigational products to a medical institution before the clinical trial contract is concluded is expressly prohibited. | Article 11 | Dated clinical trial contract execution preceding (or same day as) the earliest investigational-product shipment record to that site | An investigational product shipped to a site "to save time" ahead of final contract execution — a bright-line, low-ambiguity document-date check, analogous in spirit to Regscribe's GLP rubric's protocol-approval-must-precede-study-start check (21 CFR 58.120) |
Part C — Institutional Review Board (IRB): the most distinctive Japan-specific mechanism
This is the single area where J-GCP diverges most substantially and concretely from ICH E6(R3)'s IRB/IEC treatment, and the section most worth a customer-facing gap analysis surfacing prominently. ICH E6(R3) Annex 1 §1 (IRB/IEC) states general principles (independence, composition, timely review) but does not prescribe a national accreditation/"founder" regime; Japan's ordinance does, in detail, confirmed by direct read of Articles 27–34.
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 6 | The head of a medical institution must have the trial reviewed by an IRB drawn from one of eight named categories of eligible "founders" — an IRB established by the institution itself, or by a General Incorporated Association/Foundation, a specified NPO, an academic society of healthcare professionals, an incorporated educational institution with a medical institution, an Incorporated Administrative Agency providing medical care, an Incorporated National University with a medical institution, or a Local Incorporated Administrative Agency with a medical institution. | Article 27, Paragraph 1, Items (1)–(8) | Written confirmation of which of the 8 founder categories the IRB used for the trial falls under, with supporting incorporation/founding documents | Using an IRB whose "founder" organization does not clearly fall into one of the 8 enumerated categories (e.g., an informal or ad hoc committee with no qualifying institutional sponsor) — a threshold eligibility gate with no ICH E6 equivalent; ICH E6 does not enumerate which classes of organization may lawfully found an ethics review body |
| 7 | Non-institution-founded IRBs (Article 27, Items (2)–(4): incorporated association/foundation, NPO, academic society) must meet founder-level governance requirements: a founding-document provision establishing the IRB; at least one healthcare-professional executive director; no more than one-third of executive directors drawn from persons closely tied to a single medical institution or a single closely-related juridical person; a sufficient financial basis to operate the IRB; and public disclosure of financial documents (asset inventory, balance sheet, P&L, business report). | Article 27, Paragraph 2, Items (1)–(6) | Founder's articles of incorporation; executive-director roster with healthcare-professional composition and the one-third caps verified; publicly accessible financial-document repository | An independent/commercial IRB whose executive-director composition breaches the one-third "close relationship" cap (e.g., dominated by employees of the sites that pay it), or that does not actually publish its financial statements as required — this directly targets the conflict-of-interest risk of Japan's for-profit/commercial IRB market, a structural feature ICH E6 does not need to address because it doesn't regulate IRB "founders" as legal entities in the first place |
| 8 | The IRB itself must be composed of at least 5 members, capable of reviewing both ethical and scientific appropriateness, and must include: at least one non-specialist member (someone without medicine/dentistry/pharmacy/healthcare/clinical-trial expertise), and members independent of both the medical institution and the IRB's founder. | Article 28, Paragraph 1, Items (1)–(5) | IRB roster demonstrating the 5-member minimum, the lay/non-specialist seat, and both independence categories filled by named individuals (not by title alone) | A 5-member IRB that technically has a "lay member" seat but the individual filling it has an undisclosed close professional tie to the institution or founder — reviewers should check the actual independence of named individuals, not just that a labeled seat exists, mirroring the same "independence in name only" pattern flagged in Regscribe's GLP rubric for QAU independence |
| 9 | Certain IRB members are categorically barred from deliberating or voting on a given trial: persons closely related to the sponsor, the sponsor-investigator (or persons closely related to them), and the heads of participating medical institutions, investigators, or clinical research coordinators. Members who did not participate in deliberation may not vote. | Article 29, Paragraphs 1–2 | IRB meeting minutes showing named recusals matching the categorical bar list, and confirmation that only members present for the actual deliberation cast a vote | A member with an undisclosed sponsor relationship voting on that sponsor's trial, or a written "unanimous approval" record that doesn't actually document who was present for deliberation versus who merely signed off after the fact |
| 10 | The head of the medical institution may seek a second, "expert IRB" opinion on specialized matters beyond the primary IRB's competence, via a separate written contract with the expert IRB's founder, with the primary IRB required to consider the expert IRB's reported opinion in reaching its own. | Article 30, Paragraphs 4–7; Article 32, Paragraphs 2, 5 | Expert-IRB engagement contract (mirroring the Article 12 outsourcing-contract structure); documentation that the primary IRB's final opinion references/considers the expert IRB's input rather than ignoring it | A specialized/complex trial (e.g., novel modality, pediatric, oncology combination) reviewed only by a generalist IRB with no documented consideration of whether an expert-IRB consultation was warranted — a genuinely Japan-specific two-tier review mechanism with no ICH E6 analogue |
| 11 | Where the clinical trial exceeds one year, the head of the medical institution must seek the IRB's opinion on continuing appropriateness at least once a year; continuing review must also be triggered by specified safety notifications (Articles 20/26-6/48) or sponsor/investigator reports (Article 54, Paragraph 3), and by monitoring/audit reports reaching the institution. | Article 31, Paragraphs 1–4 | Annual continuing-review IRB opinion on file for any trial running >1 year; IRB opinion records demonstrably triggered by the specific named safety/monitoring events, not just the calendar-driven annual review | Continuing review treated as a purely calendar-driven, rubber-stamp annual event with no evidence that safety-notification-triggered reviews (Article 31 Para 2) are being separately actioned when SAEs or monitoring findings actually occur mid-year |
Part D — Medical Institution, Investigator, and Clinical Research Coordinator / SMO structure
The Clinical Research Coordinator (CRC) role and the commercial Site Management Organization (SMO) industry that supplies most Japanese CRCs are the second most distinctive Japan-specific feature, though notably the ordinance itself defines the CRC role narrowly and does not use or define the term "SMO" anywhere in its own text — SMO is industry/market terminology for the commercial vendor structure that supplies CRCs and site-management-associate staff to medical institutions, not a defined regulatory category in the ordinance. This distinction matters for Regscribe's rubric design: a gap-analysis check cannot cite an "SMO article" because none exists — SMO-supplied staff are regulated through the ordinary "clinical research coordinator" and "outsourcing" (Article 39-2) provisions below, and through the sponsor/investigator's own accountability for delegated work, not through any SMO-specific clause.
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 12 | A medical institution must be well-equipped with facilities/personnel for necessary clinical observations and lab tests, capable of emergency response, and have adequate investigators, pharmacists, nurses, and other personnel for proper conduct. | Article 35, Items (1)–(3) | Site qualification/feasibility assessment on file confirming staffing and facility adequacy | A site selected primarily for enrollment-speed reasons without a documented facility/staffing adequacy assessment |
| 13 | "Clinical research coordinators" — defined narrowly as pharmacists, nurses, or other healthcare professionals who collaborate in trial-related activities under the supervision of the investigator or subinvestigator — must have their assigned duties documented by the investigator, and must be excluded from IRB deliberation/voting on the trial they support. | Article 2, Paragraph 18 (definition); Article 43, Paragraph 1 (delegation-of-duties list); Article 29, Paragraph 1, Item (3) (IRB voting bar) | Investigator-prepared CRC duty-delegation list; confirmation no CRC involved in the trial sits on that trial's IRB review | A CRC (whether institution-employed or SMO-dispatched) performing duties never itemized in the investigator's delegation list — the CRC's legal accountability runs through the investigator's supervision regardless of whether the CRC's employer is the hospital or a commercial SMO, so a delegation list gap is a compliance gap even if the SMO's own internal contract looks complete |
| 14 | When the medical institution outsources any conduct-related duty (which is how SMO engagements are formally captured in the ordinance's own terms), a written contract must specify scope, operating procedures, the institution's right to verify compliance, instructions given, and contractor reporting obligations — materially the same contract-content structure as the sponsor-side Article 12 outsourcing provision. | Article 39-2, Items (1)–(7) | The institution-SMO contract itself, checked against all seven enumerated elements | An SMO/CRC-dispatch arrangement documented only via a staffing/dispatch agreement (names, hours, billing) with no Article 39-2-compliant scope/oversight/reporting content — this is the single highest-value, Japan-specific automatable check for any Regscribe customer using SMO-staffed Japanese sites, since SMOs cover an estimated ~70% of Japanese trial sites per industry sources (flagged as trade-press-sourced, not independently verified this session) |
| 15 | The investigator must have sufficient time, be well-versed in the protocol/Investigator's Brochure, and be qualified by education/training/clinical experience; the investigator retains inspection/oversight responsibility over subinvestigators and CRCs regardless of who employs them. | Article 42, Items (1)–(3); Article 43, Paragraph 2 | Investigator CV/training file; documented briefing of subinvestigators/CRCs on trial-specific safety notifications and duties | An investigator who has formally "delegated" oversight of SMO-supplied CRCs without retaining any documented supervisory touchpoint — same "delegation without retained oversight" pattern flagged in Regscribe's ICH E6 rubric (Part D, row 8) for investigator oversight of delegated tasks generally, here made concrete by Japan's heavy reliance on externally-supplied CRC staff |
Part E — Informed consent: Japan-specific procedural requirements
ICH E6(R3) Annex 1 §2.8 covers informed consent generally (including remote/electronic consent). J-GCP's Articles 50–55, read in full, add specific witness and written-information-content requirements not framed identically in the ICH text.
| # | Requirement | Citation | Evidence | Common failure pattern |
|---|---|---|---|---|
| 16 | Written informed consent must be obtained before participation via written information given "so that he or she will understand"; a subject incapable of giving consent may be enrolled only via a legally acceptable representative's consent, and — where no clinical benefit is anticipated to the subject — such incapable subjects may not be enrolled at all except in the two named emergency/life-threatening carve-outs (Article 7 Para 2/3; Article 15-4 Para 2/3). | Article 50, Paragraphs 1, 2, 4 | Signed ICF; for representative-consent cases, a documented record of the relationship between the representative and the subject (a distinct, separately-required record) | Representative consent obtained and documented, but the relationship record (e.g., parent, spouse, guardian, "other person considered to be such a representative") required by Article 50 Paragraph 3 is missing or informal — a specific, citable Japan document-completeness gap |
| 17 | Written information given to a prospective subject must include 17 enumerated elements (research nature; objectives; investigator contact; design; expected benefit/no-benefit statement; alternatives; duration; right to withdraw without disadvantage; monitor/auditor/IRB direct-access-to-source-documents disclosure; confidentiality; trial-injury contact/treatment/compensation; which IRB(s) reviewed the trial; subject-borne expenses; etc.), must not contain language that waives or appears to waive legal rights or reduce sponsor/investigator liability, and must use plain wording. | Article 51, Paragraphs 1 (17 items), 2, 3 | ICF/written-information document checked item-by-item against the 17-element list; language review confirming no liability-waiver phrasing | A trial-injury compensation section that is present but vague enough to functionally reduce disclosed sponsor liability — the ordinance explicitly bars language that "appears to" reduce liability, a slightly stronger and more explicit anti-waiver standard than some jurisdictions' informed-consent rules state in plain text |
| 18 | Where a prospective subject is incapable of reading the written information (and is not already covered by the incapable-of-consent representative-consent pathway), the consent process must be conducted in the presence of a witness, and that witness may not be the investigator, subinvestigator, or a clinical research coordinator involved in the trial. | Article 52, Paragraphs 3–4 | Signed consent form showing witness signature/date, with witness identity confirmed as independent of the trial team | A witness requirement satisfied on paper by a staff member who is, in substance, a CRC for the trial under a different job title — the ordinance's specific exclusion of "clinical research coordinator" by name from the witness role is a granular, easily-missed Japan-specific check |
| 19 | If new information emerges that might influence a subject's willingness to continue participating, the investigator must immediately provide it, document the communication, ascertain continued willingness, revise the written information as needed, and re-obtain consent following the same Articles 51–53 process. | Article 54, Paragraphs 1–3 | Documented re-consent record tied to the specific triggering safety/informational event, with a dated revised ICF version | Re-consent treated as a one-time administrative refresh rather than tied to a specific, named triggering event — the same "ICF not re-executed against a specific new-information trigger" pattern flagged in Regscribe's ICH E6 rubric (Part D, row 10) |
| 20 | A life-saving clinical trial in case of emergency may enroll a subject without any consent (subject or representative) only where all five conditions are met: obvious life-threatening emergency; current treatments unlikely to be sufficiently effective; sufficient possibility the test drug saves the subject's life; potential trial disadvantages minimized; and the legally acceptable representative cannot be immediately reached. | Article 55, Paragraphs 1 (5 conditions), 2 | Documented contemporaneous assessment against all 5 named conditions, plus prompt post-enrollment provision of trial information and consent-seeking once feasible | Emergency enrollment invoked without a contemporaneous, condition-by-condition documented justification — this is a narrow, tightly-conditioned exception and should be treated as a high-scrutiny gate in any Regscribe scoring logic, not a general emergency-research allowance |
Part F — Japan's Clinical Trials Act (2018) — a different, complementary regime, not a GCP-ordinance amendment
This is a scope boundary worth flagging explicitly rather than assuming: Japan's Clinical Trials Act ("Act on Clinical Trials," commonly abbreviated CTA in the English-language literature, enacted by the National Diet in 2017 and effective April 2018) is a separate statute, not part of this Ministerial Ordinance or the PMD Act. Based on secondary-source summaries (not independently fetched/read in full this session — see Sources section), the CTA's scope is: noncommercial, investigator-initiated ("academic") clinical research that either (a) tests an unapproved drug/device or an approved drug/device for an off-label use, or (b) receives funding or in-kind benefits from a pharmaceutical/device manufacturer — termed "specified clinical trials" (特定臨床研究) and subject to CTA obligations (a CTA-specific ethics-committee certification regime, conflict-of-interest disclosure, and government registration), distinct from this Ministerial Ordinance's PMD-Act-track drug/biologic registration trials governed by GCP. Before the CTA, such academic/investigator-funded research operated only under non-binding Ethical Guidelines. Practical implication for Regscribe: a Japanese trial should be classified up front as either (i) a PMD-Act registration trial (this rubric governs), (ii) a CTA "specified clinical trial" (a different statute and different oversight body — a certified/accredited Clinical Research Review Board, not the GCP Ordinance's IRB regime — governs), or (iii) non-specified academic research under the Ethical Guidelines only. This rubric does not cover the CTA itself — flagged as a distinct, not-yet-built rubric candidate if Regscribe needs to score investigator-initiated academic research specifically (see Gaps, item 4).
Part G — Failure patterns and enforcement context
Sourcing note, stated plainly: unlike the ICH E6 rubric's EMA GCP IWG annual-report data or the GLP rubric's FDA BIMO data, no PMDA-published aggregate GCP-inspection-finding dataset was located this session. The two sources below are the strongest that were found — one peer-reviewed and directly on-point but not independently fetched in full, one a well-documented scandal that is [ANALOGOUS] rather than a direct GCP-Ordinance-article enforcement precedent (it centered on academic-paper data manipulation and a false-advertising prosecution, not a PMDA GCP-inspection finding against this ordinance specifically).
- [REPRESENTATIVE] Peer-reviewed GCP-violation frequency data (2007–2017): per a WebSearch-summarized description of a PMC-indexed article studying NDA/sNDA submissions in Japan, of 985 NDAs/sNDAs subject to GCP on-site inspection between 2007–2017, 37 cases across 33 applications showed GCP non-compliance (1 at sponsor level, 32 at trial-site level). Of the 32 site-level cases, 9 were "general findings" (of which IRB-related problems were the most common category, 44.4%) and 28 were "findings for individual subjects" (of which faulty record-keeping was the most common, 60.7%). Violations clustered in 2007 and 2009, with few found after 2013 — directionally suggesting either genuine compliance improvement or reduced inspection intensity/detection over time (the source data doesn't distinguish; not editorializing beyond what's confirmed). Not independently fetched/read in full this session — flagged as a follow-up before citing exact percentages in customer-facing output. The IRB-finding and record-keeping-finding categories align directly with Parts C and D above, reinforcing that Regscribe's highest-value J-GCP document checks are IRB-process completeness and site-level record contemporaneity/completeness.
- [ANALOGOUS] The Diovan (valsartan) data-manipulation affair: a Novartis Pharma K.K. employee (Nobuo Shirahashi) was arrested in June 2014 on suspicion of falsifying clinical-trial data used in academic papers claiming cardiovascular benefits of Diovan (valsartan) beyond its approved blood-pressure indication, following studies conducted at multiple Japanese universities (reporting per Lancet/NEJM-blog/Fierce Pharma coverage, not independently fetched this session). A Tokyo court reportedly acquitted both Novartis and the employee on the specific criminal charge (unauthorized/false pharmaceutical advertising) in 2017, while not disputing that the underlying data had in fact been manipulated — the acquittal turned on whether an academic journal article constituted "advertising" under Japanese law, not on whether the data was falsified. This is Japan's most widely-cited clinical-research-integrity scandal, but it is not a GCP-Ordinance Article violation finding — the affected studies were investigator-initiated academic trials of an already-approved drug, predating the 2018 Clinical Trials Act that was specifically enacted partly in response to this affair to close the regulatory gap it exposed (this causal linkage is asserted in secondary commentary, e.g. the Journal of Human Hypertension piece, but was not independently confirmed against a Diet/MHLW legislative-history document this session). Use with the caveat stated: illustrative of why Japan built its CTA oversight gap-closing regime (Part F), not evidence of a GCP-Ordinance-specific enforcement failure.
Cross-reference: J-GCP vs. ICH E6(R3) — where they actually differ
| Concept | J-GCP (this ordinance) | ICH E6(R3) treatment |
|---|---|---|
| IRB "founder" eligibility/governance | Prescribed: 8 enumerated eligible founder categories (Art. 27), governance requirements incl. 1/3-independence caps and public financial disclosure (Art. 27 Para 2) | General independence/composition principles only (Annex 1 §1); no founder-entity regime |
| Second-opinion / "expert IRB" mechanism | Formal two-tier review process with its own contract requirements (Art. 30, 32) | No equivalent formal mechanism |
| Sponsor vs. sponsor-investigator structural duality | Nearly every article duplicated across two full parallel tracks (Ch. II §1/§2, Ch. III §1/§2) | Investigator-sponsor addressed but not organized as a parallel full-ordinance duplicate structure |
| CRC / SMO-supplied staff | CRC narrowly defined (Art. 2 ¶18); SMO itself undefined in the ordinance — governed via ordinary outsourcing (Art. 39-2) and delegation (Art. 43) provisions | No CRC/SMO-specific concept; "delegated tasks" addressed generically (Annex 1 §2.3) |
| Informed-consent witness rule | Explicit witness requirement for subjects incapable of reading written information, with CRCs/investigators expressly barred from serving as witness (Art. 52) | No equivalent explicit witness-exclusion rule in the Annex 1 §2.8 text as rubric'd |
| In-country representative for foreign sponsors | Mandatory named role with defined record-retention duties (Art. 15, 26 ¶2) | No ICH E6 equivalent (a national-regulatory-filing concept, not a GCP-principle concept) |
| Non-drug academic clinical research | Out of scope for this ordinance entirely — governed by the separate 2018 Clinical Trials Act | Out of scope for ICH E6 as well (both instruments are drug/biologic-registration-trial-focused) |
Gaps / follow-ups before this goes into production scoring
- Translation currency gap — the single most important flag in this document. PMDA's own English GCP-ordinance page states the Japanese-language ordinance was last amended December 2023, while the only English translation locatable and read this session is marked "Provisional Translation (as of January 2023)" reflecting amendments only through MHLW Ordinance No. 84 of May 20, 2022. This rubric's article numbers and content should be treated as verified current through mid-2022, with the nature and content of any subsequent (2022–2023, possibly later) amendment unconfirmed from an English-language source. Recommend a dedicated follow-up: check
pmda.go.jp/english/review-services/glp-gcp-gpsp/0003.html(or equivalent) periodically for an updated English translation, and treat any customer-facing claim about "current" Article numbering as provisional until reconfirmed. - PMDA does not appear to publish an aggregate, English-language GCP-inspection-finding statistics report analogous to FDA's BIMO metrics or EMA's GCP IWG annual report. The one dataset used here (Part G, item 1) is peer-reviewed and directly on-point but was sourced via WebSearch snippet, not independently fetched and read in full — recommend a follow-up direct fetch/read of the PMC6682372 (or correctly-identified equivalent) article before citing its percentages in customer-facing output.
- The Diovan/valsartan scandal (Part G, item 2) was sourced entirely via WebSearch summaries of secondary press/journal coverage, not a primary court document, MHLW enforcement notice, or PMDA statement. The broad facts (arrest, data manipulation, 2017 acquittal on the advertising charge specifically) are treated as high-confidence given multiple independent outlets, but exact case citations, court name, and precise legal reasoning are unverified — do not present this in Regscribe's UI as a "GCP Ordinance enforcement precedent" without the caveat that it was an academic-research/advertising-law matter, not a PMDA GCP-inspection finding under this ordinance.
- Japan's 2018 Clinical Trials Act (CTA) governing non-drug/investigator-initiated "specified clinical trials" was described here only via secondary-source summary (Part F) and was not independently fetched/read this session. If Regscribe needs to score compliance for academic/investigator-initiated Japanese research specifically (as opposed to PMD-Act registration trials), the CTA needs its own dedicated primary-source research pass and likely its own separate rubric — it is a different statute with a different oversight body (certified Clinical Research Review Boards, not this ordinance's IRB regime), not a subset of this document.
- The ~70% SMO-site-coverage figure (Part D, row 14) is sourced from industry/trade-press commentary (Advarra, EPS Global, ClinicalTrialsArena), not a PMDA or government statistic — treat as directionally indicative of SMO market importance, not as a verified regulatory data point.
- No named, recent (2023–2026), PMDA-attributed GCP Ordinance violation case was found or verified this session, in contrast to the ICH E6 rubric's EMA IWG 2023 data or the GLP rubric's historical FDA/DOJ cases. This is a materially thinner enforcement-precedent base than Regscribe's other rubrics and should be flagged to any human reviewer relying on this document for severity-weighting decisions.
- Cross-reference table completeness: the Part H cross-reference table above covers the concepts this session's research converged on as most distinctive; it has not been cross-checked line-by-line against every one of ICH E6(R3) Annex 1's sub-clauses for exhaustiveness — recommend a follow-up reconciliation pass once both this rubric and the ICH E6 rubric are being jointly used in production scoring, similar to the reconciliation follow-up already flagged between the ICH E6 and ISO 14155 rubrics.